Gene Malin

Dr. Gene Malin


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
JKJune Kim
June Kim
RSRamin Sabet-Azad
Ramin Sabet-Azad
DPDimki Patel
Dimki Patel
GMGene Malin
Gene Malin
SASyed Hassan Askary
Syed Hassan Askary
ASAnna Saernefaelt
Anna Saernefaelt
CEPI (the Coalition for Epidemic Preparedness Innovation)’s CMC rapid response framework is developed to support accelerated vaccine development, manufacturing, and roll-out for various outbreak scenarios to achieve the 100 Days Mission. The framework outlines coordinated deliverables across five functional areas: manufacturing processes, formulation, analytics, supply chain, and facilities. It could serve as a tool to streamline CMC and the related activities for rapid vaccine development, identify areas for improvement and innovation, and assess preparedness for the outbreak response. The framework emphasizes the importance of thorough preparation during interpandemic periods as the foundation for the 100 Days Mission and for gaining the confidence of health authorities and the public in vaccines.

28 March 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
MKMITSUTAKA KITANO
MITSUTAKA KITANO
BSByoung-Shik Shim
Byoung-Shik Shim
HSHitoshi Sasaki
Hitoshi Sasaki
JLJonathan Lovell
Jonathan Lovell
VKV. Narry Kim
V. Narry Kim
TETimothy Endy
Timothy Endy
On 9–10 December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) convened a workshop in Seoul under CEPI’s Disease X Program. The primary objective was to identify existing gaps needing to be filled and streamline vaccine development and preparedness for Severe Fever with Thrombocytopenia Syndrome (SFTS). CEPI’s partners and experts discussed a multifaceted agenda, ranging from understanding the evolving epidemiology to the refinement of animal models and immunological assay harmonization. Key outcomes included the refinement of Target Product Profiles (TPPs) specifying use cases for both peacetime and outbreak contexts, alongside a recommendation for a core immunoassay panel aimed at harmonizing evaluation frameworks and mitigating the challenges posed by low SFTS prevalence. Integration of the One Health approach emerged as a critical strategy for SFTS prevention, complemented by proactive regulatory engagement to compress vaccine development timelines. This report summarizes these key insights from the workshop, delineating a strategic framework for delivering safe, effective, and accessible vaccines for SFTS and broader Disease X threats.